Search clinical trials for: Injectable HDV-Interferon ribavarin

Total 537 results

National Institute of Allergy and Infectious Diseases...

Completed

Nitazoxanide Plus Ribavirin and Peginterferon for Therapy of Treatment Naive HCV Genotype 1 and HIV Coinfected Subjects

HIV Infection | Hepatitis C Infection

United States, Puerto Rico
Melbourne Health
Hoffmann-La Roche; Monash University; The University of New South Wales; St Vincent... and other collaborators

Completed

Pegylated Interferon and Ribavirin in Hepatitis C Patients on Opioid Pharmacotherapy

Chronic Hepatitis C

Australia
Icahn School of Medicine at Mount Sinai
National Institute on Alcohol Abuse and Alcoholism (NIAAA); Hoffmann-La Roche

Completed

Antiviral & Antifibrotic Liver Therapy in HCV + Drinkers and Non-Drinkers

Hepatitis C

United States
The University of Texas Health Science Center,...
Astellas Pharma US, Inc.

Withdrawn

Orthotopic Liver Transplant (OLT) Recipients With Hepatitis C Virus (HCV) Under Preemptive Treatment

Hepatitis C

United States
ANRS, Emerging Infectious Diseases
Institut Pasteur

Withdrawn

Efficacy and Safety of the Combination Vitamin D With Standard of Care in Egyptian Patients With Untreated Chronic Hepatitis C (ViZIR)

Chronic Hepatitis C

Egypt
Janssen-Cilag International NV

Completed

A Study of TMC435 Plus Pegylated Interferon Alfa-2a and Ribavirin in Participants With Chronic HCV Infection

Hepatitis C, Chronic | Infection

United Kingdom, Germany, Spain, Belgium, Saudi Arabia, Austria, France
Beijing Ditan Hospital

Unknown

An Observational Cohort Study of Clinical Outcomes After Antiviral Treatment of Chronic Hepatitis C

Chronic Hepatitis C

China
Dr. Nadia AbdelAaty AbdelKader

Terminated

Long Term Vitamin D Therapy in HCV Treated Patients (VD-HCV)

Chronic Hepatitis C

Egypt
Bristol-Myers Squibb

Completed

Safety and Efficacy Study of Daclatasvir (BMS-790052) Plus Pegylated Interferon-Alfa 2a and Ribavirin in Patients Coinfected With Untreated Hepatitis C Virus and HIV Virus

Hepatitis C, Genotype 1

United States, Australia, France, Germany, Spain, Canada, Puerto Rico, Argentina, Brazil, Russian Federation, United Kingdom, Italy, Belgium
National Taiwan University Hospital
National Science Council, Taiwan

Unknown

Early Prediction of Successful Treatment for Chronic Hepatitis C Virus Infection in Taiwan

Chronic Hepatitis C

Taiwan, Israel
Bristol-Myers Squibb

Withdrawn

Safety and Efficacy Study of Pegylated Interferon Lambda Versus Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C

Hepatitis C Virus (HCV)

India, Korea, Republic of, Poland, Taiwan, Spain, Canada, Russian Federation, Colombia, Singapore, Netherlands, Ireland, United Kingdom, Czech Republic, Hungary, Romania, Hong Kong, Turkey, United States, China, Egypt
Merck Sharp & Dohme LLC

Completed

Boceprevir in Subjects With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Peginterferon/Ribavirin (Study P05101AM3)(COMPLETED)

Hepatitis C, Chronic
Center For Hepatitis C, Atlanta, GA

Completed

The SIM-SOF Trial for Hepatitis C

Chronic Hepatitis C

United States
Sheikh Zayed Medical College

Completed

Impact of Interleukin 28B (rs12979860) Genotype on Virological Responses Chronic Hepatitis C Treatment

Hepatitis C | Hepatitis C Relapse

Pakistan
Kirby Institute
The University of New South Wales; Virax Pty. Ltd,

Completed

ITV Extension Study

HIV

Australia
Children's Hospital of Fudan University
Changhai Hospital; Hunan Children's Hospital; Yuying Children's Hospital of Wenzhou... and other collaborators

Completed

Effect of Recombinant Human Interferon α-2b Spray on Herpangina

Herpangina

China
University Hospital, Geneva

Completed

Ribavirin/Pegasys Treatment of Recurrent Hepatitis C After Liver Transplant

Hepatitis C
Bristol-Myers Squibb

Completed

Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives) (Hallmark DUAL)

Hepatitis C Virus

France, Germany, Korea, Republic of, Spain, Taiwan, United States, Canada, Australia, Russian Federation, Austria, Israel, Italy, Netherlands, Argentina, Poland, United Kingdom, Ireland, New Zealand
Weill Medical College of Cornell University
National Institute of Allergy and Infectious Diseases (NIAID)

Terminated

Safety Study of Low Dose Interleukin 2 (IL-2) Plus PEG-IFN/RBV In Chronic Hepatitis C Virus Genotype I

Hepatitis C

United States
French National Agency for Research on AIDS and...
Hoffmann-La Roche

Completed

Efficacy and Safety of Addition of IL-2 to Pegylated Interferon Alpha 2a and Ribavirin in HIV/HCV Coinfected Patients

HIV Infections | Chronic Hepatitis C

France
Merck Sharp & Dohme LLC

Completed

Safety and Efficacy of Vaniprevir (MK-7009) With Pegylated Interferon (Peg-IFN) and Ribavirin (RBV) in Treatment-Experienced Hepatitis C Virus (HCV) Participants (MK-7009-009)

Hepatitis C, Chronic
National Institute of Allergy and Infectious Diseases...

Completed

A Comparison of the Effectiveness, Safety, and Tolerability of Two Different Hepatitis C Treatments in Patients Infected With Both HIV and Hepatitis C Virus (HCV)

HIV Infections | Hepatitis C

United States
Hoffmann-La Roche

Completed

The Individualized Management With Pegylated-interferon Alfa-2a (Pegasys) and Ribavirin (Copegus) Offering Viral Eradication: A Study of Pegylated-interferon Alfa-2a Plus Ribavirin in Participants With Chronic Hepatitis C (CHC) Non-genotype 2/3 (IMPROVE) (IMPROVE)

Hepatitis C, Chronic

Canada, United States
Hoffmann-La Roche

Terminated

An Observational Study of Pegasys (Peginterferon Alfa-2a) Plus Ribavirin Based Regimens in Patients With Chronic Hepatitis C With Previous Treatment Failure

Hepatitis C, Chronic

Romania
Janssen-Cilag International NV

Completed

Open-Label, Bridging Study of Telaprevir in Treatment-Naïve and Treatment-Experienced Russian Patients With Genotype 1 Chronic Hepatitis C

Genotype 1 Chronic Hepatitis C

Russian Federation
Janssen Infectious Diseases BVBA
Vertex Pharmaceuticals Incorporated

Completed

VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naïve Participants With Genotype 1 Chronic Hepatitis C Virus Infection

Genotype 1 Chronic Hepatitis C | Treatment Naive

United States, Australia, France, Poland, United Kingdom, Belgium, Germany, Spain, Sweden, Brazil, Austria, Ireland, Mexico
Tibotec BVBA

Completed

An Exploratory Study of Telaprevir in Treatment-Naive Participants With Chronic Genotype 4 Hepatitis C Virus Infection

Hepatitis C
Human Genome Sciences Inc.
Novartis

Completed

Efficacy of Albumin Interferon Alfa-2b With Ribavirin Compared With Peg-IFN Alfa-2a With Ribavirin in IFN Naive Patients

Chronic Hepatitis C

United States, Spain, Canada, France, Australia, Italy, Israel, Poland, United Kingdom, Germany, Czech Republic, Romania, Austria, India, Puerto Rico
Hoffmann-La Roche

Completed

A Study of Predictors of the Effectiveness of Pegylated Interferon in a Cohort of Participants With Hepatitis C

Hepatitis C, Chronic

Georgia
Bausch Health Americas, Inc.

Completed

Study of Viramidine to Ribavirin in Patients With Chronic Hepatitis C Who Are Treatment-Naive

Chronic Hepatitis C
Centre Hospitalier Universitaire de Nice

Not yet recruiting

Interferon Alfa Therapy Based on Th17 Profile in Membranous Nephropathy (ALPHAGEM)

Membranous Nephropathy

France
Conatus Pharmaceuticals Inc.

Completed

Study of CTS-1027 in Combination With Pegylated Interferon and Ribavirin in Hepatitis C Virus (HCV) Null-Responders (CTS-1027-04)

Hepatitis C

United States, Puerto Rico
Bausch Health Americas, Inc.

Completed

Daily-Dose Consensus Interferon and Ribavirin: Efficacy of Combined Therapy

Chronic Hepatitis C
Merck Sharp & Dohme LLC

Terminated

Study of Response in Chronic Hepatitis C (CHC) Participants Genotype 1 With Insulin Resistance and Prolonged Treatment Duration in Late Responders (P04823/MK-4031-303)

Hepatitis C, Chronic | Insulin Resistance
King Abdulaziz Medical City
King Faisal Specialist Hospital & Research Center; Riyadh Military Hospital

Completed

Peginterferon Alfa-2a Plus Ribavirin Combination Treatment in Chronic Hepatitis C Post-Renal Transplant Patients

Chronic Hepatitis C | Renal Transplant

Saudi Arabia
The University of Hong Kong
Hospital Authority, Hong Kong

Completed

Lopinavir/ Ritonavir, Ribavirin and IFN-beta Combination for nCoV Treatment

Novel Coronavirus Infection

Hong Kong
HepNet Study House, German Liverfoundation
Hannover Medical School

Terminated

Study to Assess the Efficacy of 12 Versus 24 Weeks of Extended Treatment in HCV-Genotype 2/3 Patients (OPTEX2/3)

Hepatitis C, Chronic

Germany
Foundation for Liver Research

Completed

High-dose IFN and PEG IFN for Induction Therapy in Difficult to Treat Genotype 1 Patients With Chronic HCV

Hepatitis C

Netherlands
Janssen-Cilag International NV

Completed

An Efficacy and Safety Study of Telaprevir in Patients With Genotype 1 Hepatitis C Infection After Liver Transplantation (REPLACE)

Chronic Hepatitis C Virus (HCV) Infection

France, United Kingdom, Spain, Germany, Belgium, Austria
University Hospital, Basel, Switzerland

Completed

Chronic Hepatitis C Non-Responder Study With AdoMet and Betaine

Hepatitis C

Switzerland
Kirby Institute
Merck Sharp & Dohme LLC

Completed

A Collaborative Trial in Injectors of Individualized Treatment for Genotype 2/3 (ACTIVATE)

Hepatitis C, Chronic

Australia, Canada, United Kingdom, Belgium, Germany, Norway, Switzerland
The University of Hong Kong
Hospital Authority, Hong Kong

Unknown

IFN Beta-1b and Ribavirin for Covid-19

Covid19

Hong Kong
Hoffmann-La Roche

Completed

Observational Study Evaluating the Quality of Pegylated Interferon Alfa-2a and Ribavirin Treatment for Chronic Hepatitis C in Cooperation With the BNG (Association of German Resident Gastroenterologists)

Chronic Hepatitis C

Germany
University Hospital, Geneva

Completed

Retreatment of Chronic Hepatitis C Non-responders With Pegylated Interferon Alpha Plus Ribavirin Plus Pioglitazone

Chronic Hepatitis C

Switzerland
Human Genome Sciences Inc.
Novartis

Completed

Efficacy of Albumin Interferon Alfa-2b With Ribavirin Compared to Peg-IFN Alfa-2a With Ribavirin in IFN Naive Patients Geno2/3

Chronic Hepatitis C

Korea, Republic of, United States, Spain, Canada, France, Australia, Israel, Singapore, Thailand, Malaysia, Sweden, Belgium, Germany, Taiwan, Poland, Argentina, India, Puerto Rico, Brazil, Mexico, United Kingdom
Bausch Health Americas, Inc.

Completed

Daily-Dose Consensus Interferon and Ribavirin: Efficacy of Combined Therapy

Chronic Hepatitis C
Merck Sharp & Dohme LLC

Terminated

Efficacy and Safety of 24 vs 48 Weeks of Pegetron® (Peginterferon Alfa-2b + Ribavirin) in Naïve Genotype 1 Hepatitis C (Study P05016)(TERMINATED)

Hepatitis C, Chronic
Merck Sharp & Dohme LLC

Withdrawn

Study to Evaluate Different Regimens of Vaniprevir (MK7009) for the Treatment of Chronic Genotype 1 Hepatitis C Virus Infection in Treatment-naive Patients (MK-7009-019)(WITHDRAWN)

Chronic Genotype 1 Hepatitis C Virus Infection
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI)

Terminated

Effect of Biological Therapy on Biomarkers in Patients With Untreated Hepatitis C, Metastatic Melanoma, or Crohn Disease

Melanoma
Sheba Medical Center

Unknown

Clinical Trial to Assess Safety and Efficacy of Combination Therapy: Hydroxychloroquine, Pegylated Interferon Alpha-2a and Ribavirin in Chronic Hepatitis C Subjects Non-responders to the Standard of Care Therapy.

Chronic Hepatitis C

3

Subscribe